<DOC>
	<DOCNO>NCT02035605</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics ALN-AT3SC healthy volunteer Hemophilia A B patient .</brief_summary>
	<brief_title>A Phase 1 Study Investigational Drug , ALN-AT3SC , Healthy Volunteers Hemophilia A B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Part A ( SAD phase ) inclusion : Healthy adult male age 18 40 year inclusive Screening . Subjects adequate complete blood count liver function test . Willing provide write informed consent willing comply study requirement . Part B &amp; C ( MAD &amp; MD phase ) inclusion : Adult male hemophilia patient age 18 65 year inclusive Screening . Patients adequate complete blood count liver function test . Patients moderate severe , clinically stable hemophilia A B ( Factor VIII Factor IX ≤5 % ) . Willing provide write informed consent willing comply study requirement Part D ( MD Phase patient inhibitor ) Inclusion : Same Parts B/C A Bethesda inhibitor assay &gt; 0.6 BU/mL Part A ( SAD phase ) exclusion : Subjects personal history and/or family history venous thromboembolism ( VTE ) Subjects know coexist thrombophilic disorder Subjects history multiple drug allergy history allergic reaction oligonucleotide GalNAc . Subjects history serious mental illness include , limited schizophrenia , bipolar disorder , severe depression require hospitalization pharmacological intervention . Subjects clinically relevant history presence cardiovascular , respiratory , gastrointestinal , renal , hematological , lymphatic , neurological , musculoskeletal , genitourinary , immunological include osteoarthritis inflammatory disease , dermatological include rash , eczema , dermatitis , connective tissue diseases disorder . Part B &amp; C ( MAD &amp; MD phase ) exclusion : Patients current serious mental illness , judgment Investigator , may compromise patient safety , ability participate study assessment , study integrity . Patients clinically relevant history presence cardiovascular , respiratory , gastrointestinal , renal , neurological , inflammatory disease judgment investigator precludes participation study . Patients know coexist thrombophilic disorder Patients history multiple drug allergy history allergic reaction oligonucleotide GalNAc . Patients know HIV positive CD4 count &lt; 400 cells/μL Part D ( MD Phase patient inhibitor ) exclusion : Same Parts B/C Patients known HIV positive CD4 count &lt; 200 cells/μL</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>